A small air bubble at the beginning of the catheter separated aCSF-filled tubing from treatment solution, containing the EphA4 inhibitory or inactive peptide APY-d3 (30), allowing the 2-week treatment to start at 48 h after stroke (Fig. 6A). The gene discussed is EPHA4; the disease is stroke disorder.